The Association of MTHFR (C677T) and ADIPOQ (G276T) Gene Polymorphisms with Blood Lipid Levels in the Elderly
Keywords:
MTHFR (C677T), ADIPOQ (G276T), Blood lipid levels, ElderlyAbstract
The abnormal level of blood lipids is the major risk factor for cardiovascular disease. Genetic variations have been associated with altered homocysteine and adiponectin levels that involving blood lipid alteration. The aimed of this study was, therefore, to investigate the association of MTHFR C677T (rs1801133) and ADIPOQ G276T (rs1501299) polymorphisms with blood lipid levels. The study was conducted in community-based 648 Thai subjects aged ≥50 years who attended for annual health check-up at Health Center 15, Bangkok. The genotyping was performed using PCR-RFLP. Regarding MTHFR C677T, increasing level of plasma LDL-C was observed in relationship with increasing number of the minor, T allele (p for trend=0.042). Regression analysis also revealed the significant association between T allele of MTHFR C677T and the risk of having elevated LDL-C levels (≥130 mg/dL) [OR(95%CI) = 1.435 (1.073-1.920), p=0.015]. Such association was also significantly associated with the risk of having clinically low HDL-C levels [OR (95%CI) = 1.434 (1.039-1.978), p=0.033]. For ADIPOQ G276T, the decreasing levels of HDL-C levels was observed in relationship with increasing number of the minor, T allele (p-trend=0.042). The association between T allele of ADIPOQ G276T was also significantly associated with the risk of having clinically low HDL-C levels [OR(95%CI) = 1.351 (1.025-1.781), p=0.033]. The combined T allele carriers of both gene polymorphisms (CT+TT/GT+TT) increased the risk of having low HDL-C levels [OR(95%CI)=2.037 (1.215-3.417) p=0.007]. In conclusion, the risk variants of both genes which associated with the risk of blood lipids alteration may contribute to the risk of CVD.
References
WHO. Cardiovascular disease (CVDs) [online] 2016 [cited 2019 Apr 1 ]. Available from: http://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
Non communicable disease data [online] 2015 [cited 2016 Apr 1]. Available from: http://www.thaincd.com/2016/mission/documents.php?tid=32&gid=1-020
Lusis AJ. Atherosclerosis. Nature 2000; 407(6801): 233-241.
Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol 2006; 47(8 Suppl): C7-12.
Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for
vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10(1): 111-113.
Real JT, Martinez-Hervas S, Garcia-Garcia AB, Chaves FJ, Civera M, Ascaso JF, et al. Association of C677T polymorphism in MTHFR gene, high homocysteine and low HDL cholesterol plasma values in heterozygous familial hypercholesterolemia. J Atheroscler Thromb 2009; 16(6): 815-820.
Sarutipaiboon I, Settasatian N, Settasatian C, Komanasin N, Kukongwiriyapan U, Intharapetch P, et al. Association between methylenetetrahydrofolatereductase gene (MTHFR) polymorphisms and homocysteine level in Thai patients with coronary artery disease. J Med Tech Phy Ther 2013; 25(1): 1-15. Thai.
Huang T, Yuan G, Zhang Z, Zou Z, Li D. Cardiovascular pathogenesis in hyperhomocysteinemia.
Asia Pac J Clin Nutr 2008; 17(1): 8-16.
Steed MM, Tyagi SC. Mechanisms of cardiovascular remodeling in hyperhomocysteinemia. Antioxid Redox Signal 2011; 15(7): 1927-1943.
Chen S, Wu P, Zhou L, Shen Y, Li Y, Song H. Relationship between increase of serum homocysteine caused by smoking and oxidative damage in elderly patients with cardiovascular disease. International journal of clinical and experimental medicine 2015; 8(3): 4446-4454.
Lai WK, Kan MY. Homocysteine-Induced Endothelial Dysfunction. Ann Nutr Metab 2015; 67(1): 1-12
Werstuck GH, Lentz SR, Dayal S, Hossain GS, Sood SK, Shi YY, et al. Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J Clin Invest 2001; 107(10): 1263-1273.
Mikael LG, Genest J, Rozen R. Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease. Circ Res 2006; 98(4): 564-571.
Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005; 26(3): 439-451.
Filippi E, Sentinelli F, Romeo S, Arca M, Berni A, Tiberti C, et al. The adiponectin gene SNP+276G>T associates with early-onset coronary artery disease and with lower levels of adiponectin in younger coronary artery disease patients (age
Cheung CY, Hui EY, Cheung BM, Woo YC, Xu A, Fong CH, et al. Adiponectin gene variants and the risk of coronary heart disease: a 16-year longitudinal study. Eur J Endocrinol 2014; 171(1): 107-115.
Kawai T, Ohishi M, Takeya Y, Onishi M, Ito N, Yamamoto K, et al. Adiponectin Single Nucleotide Polymorphism is a Genetic Risk Factor for Stroke Through High Pulse Wave Pressure: A Cohort Study. J Atheroscler Thromb 2013; 20(2): 152-160.
Miyazaki T, Shimada K, Mokuno H, Daida H. Adipocyte derived plasma protein, adiponectin, is associated with smoking status in patients with coronary artery disease. Heart (British Cardiac Society) 2003; 89(6): 663-663.
Hector J, Schwarzloh B, Goehring J, Strate TG, Hess UF, Deuretzbacher G, et al. TNF-alpha alters visfatin and adiponectin levels in human fat. Horm Metab Res 2007; 39(4): 250-255.
Monzillo LU, Hamdy O, Horton ES, Ledbury S, Mullooly C, Jarema C, et al. Effect of lifestyle modification on adipokine levels in obese subjects with insulin resistance. Obes Res 2003; 11(9): 1048-1054.
Schneider JG, von Eynatten M, Schiekofer S, Nawroth PP, Dugi KA. Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo. Diabetes Care 2005; 28(9): 2181-2186.
Verges B, Petit JM, Duvillard L, Dautin G, Florentin E, Galland F, et al. Adiponectin is an important determinant of apoA-I catabolism. Arterioscler Thromb Vasc Biol 2006; 26(6): 1364-1369.
Jackson CF, Wenger NK. Cardiovascular disease in the elderly. Rev Esp Cardiol 2011; 64(8): 697-712.
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002; 106(25): 3143-3143.
Mackevics V, Heid IM, Wagner SA, Cip P, Doppelmayr H, Lejnieks A, et al. The adiponectin gene is associated with adiponectin levels but not with characteristics of the insulin resistance syndrome in healthy Caucasians. Eur J Hum Genet 2006; 14(3): 349-356.
Chirawatkul A. Statistics for Health Science Research. Bangkok: Witthayaphat; 2015. Thai.
Rodriguez S, Gaunt TR, Day INM. Hardy-Weinberg Equilibrium Testing of Biological Ascertainment for Mendelian Randomization Studies. Am J Epidemiol 2009; 169(4): 505-514.
Gray R, Pattaravanich U, Chamchan C, Suwannoppakoa R. New Concept of Older Presons: The Psycho-socia and Health Perspective. Nakhonpathom: Institute for Population and Social Research, Mahidol University; 2013.Thai.
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120(16): 1640-1645.
Chen W, Hua K, Gu H, Zhang J, Wang L. Methylenetetrahydrofolate reductase C667T polymorphism is associated with increased risk of coronary artery disease in a Chinese population. Scand J Immunol 2014; 80(5): 346-353.
Zhan D, Yuktanandana P, Anomasiri W, Tanavalee A, Honsawek S. Association of adiponectin +276G/T polymorphism with knee osteoarthritis. Biomed Rep 2014; 2(2): 229-232.
Katakami N, Kaneto H, Matsuoka TA, Takahara M, Maeda N, Shimizu I, et al. Adiponectin G276T gene polymorphism is associated with cardiovascular disease in Japanese patients with type 2 diabetes. Atherosclerosis 2012; 220(2): 437-442.
Jiang S, Zhao R, Pan M, Venners SA, Zhong G, Hsu YH. Associations of MTHFR and MTRR polymorphisms with serum lipid levels in Chinese hypertensive patients. Clin Appl Thromb Hemost 2014; 20(4): 400-410.
Sharpe LJ, Brown AJ. Controlling cholesterol synthesis beyond 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR). J Biol Chem 2013; 288(26): 18707-18715.
Liao D, Tan H, Hui R, Li Z, Jiang X, Gaubatz J, et al. Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I Protein synthesis and enhancing HDL cholesterol clearance. Circ Res 2006; 99(6): 598-606.
Ng TW, Watts GF, Farvid MS, Chan DC, Barrett PH. Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics? Diabetes 2005; 54(3): 795-802.
